Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
Matinas BioPharma (NYSE AMER: MTNB) will hold a conference call on January 30, 2023, at 4:30 p.m. ET to discuss its business outlook for 2023 and provide corporate updates. The call will cover details about ongoing programs and third-party collaborations. Interested participants can join via telephone or through a live webcast on the company's website, where the presentation will be archived for 90 days. Matinas focuses on enhancing intracellular delivery of nucleic acids and small molecules using its innovative lipid nanocrystal (LNC) technology, aiming to tackle challenges in drug delivery.
- Innovative lipid nanocrystal technology aims to improve drug delivery for complex molecules.
- Company is actively pursuing collaborations with major pharmaceutical firms, like BioNTech.
- None.
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET
BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced that the Company will host a conference call and live audio webcast on Monday, January 30, 2023 at 4:30 p.m. ET to provide a corporate update and discuss the Company’s business outlook for 2023. During the call, senior management will provide updates on the Company’s ongoing programs, including third party collaborations.
To participate in the call, please dial (877) 407-5976 or (412)-902-0031. The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com, and archived for 90 days.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.
For more information, please visit www.matinasbiopharma.com.
Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, our strategy and plans, our collaborations with National Resilience, Inc. and BioNTech SE, the potential of our LNC platform delivery technology, and the future development of its product candidates, the Company’s ability to identify and pursue development, licensing and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
815.721.4912
matinas@allelecomms.com
Source: Matinas BioPharma Holdings, Inc.
FAQ
When is Matinas BioPharma's conference call scheduled?
What is the focus of Matinas BioPharma's technology?
How can I join the Matinas BioPharma conference call?
What are the potential applications of the LNC technology?
Who are Matinas BioPharma's partners in development?
